Most women requiring continued cervical cancer screening — including those at high risk — do not continue screening after 65 years of age.

Cotesting, the practice of adding cytology to human papillomavirus (HPV) screening, offered little added benefit over HPV testing alone in the detection of precancer among women aged 25-65 years, ...

Global modeling reveals that without urgent action, cervical cancer inequalities will worsen, highlighting the need for ...

In 2026, cervical cancer remains a stark reminder of global health inequity, with women in low-income countries and ...